<DOC>
	<DOC>NCT00240266</DOC>
	<brief_summary>The purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.</brief_summary>
	<brief_title>Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Signed informed consent males aged 4565 insulin resistance central obesity LDLC &lt;6 mmol/L plasma triglycerides &gt;=1.7 and ≤5.5 mmol/L HDLC ≤1.2 mmol/L. total cholesterol &gt;7mmol/L preexisting cardiovascular disease, diabetes, proteinuria or renal failure</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Dyslipaemia</keyword>
</DOC>